Avertix Medical

Avertix Medical is a medical technology company founded in 2001 by Drs. Robert, Tim, and David Fischell, who are experienced entrepreneurs in cardiac medical technologies. The company is dedicated to managing cardiovascular disease through innovative implantable devices. The flagship product, the Guardian™ System, is the first FDA-approved Class III implantable device that detects acute thrombotic coronary occlusion, including silent and atypical heart attacks, in real-time. This system continuously monitors the heart for acute coronary syndrome events and provides early warnings to both patients and healthcare providers, facilitating timely medical intervention. The Guardian System has been clinically validated in the ALERTS trial, showing that it helps patients seek urgent care sooner, which can improve outcomes for high-risk heart attack survivors. Avertix Medical targets patients at high risk of recurrent heart attacks and collaborates with healthcare organizations to enhance cardiac care and patient monitoring. The leadership team includes Timothy P. Moran as President and CEO, along with other executives managing various aspects of the company.

• Employees 47
• Founded 2001
• Total Funding $87804926